Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085292 | 0.82 | KDM4E (0.57) | ALDH1A1KDM4EKMT2AGRM5LMNA | |
| SCHEMBL10574893 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4EKMT2AMEN1RAB9A | |
| SCHEMBL17188580 | 0.80 | KDM4E (0.56) | ALDH1A1KDM4EKMT2AGRM5LMNA | |
| SCHEMBL2226770 | 0.80 | — | — | |
| SCHEMBL154527 | 0.80 | — | — | |
| SCHEMBL30692446 | 0.79 | KDM4E (0.54) | ALDH1A1KDM4EKMT2AGRM5LMNA | |
| SCHEMBL4444134 | 0.78 | CA1 (0.65) | ALDH1A1KDM4ERAB9AL3MBTL1HPGD | |
| Hydrochloric Acid SCHEMBL11293911 | 0.78 | CA1 (0.65) | ALDH1A1KDM4ERAB9AL3MBTL1HPGD | |
| Iodide SCHEMBL5695908 | 0.78 | CA1 (0.65) | ALDH1A1KDM4ERAB9AL3MBTL1HPGD | |
| Water SCHEMBL9443323 | 0.78 | CA1 (0.65) | ALDH1A1KDM4ERAB9AL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | ALDH1A1 545/4885KDM4E 3258/4885KMT2A 3471/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | ALDH1A1 194/4885KDM4E 2184/4885KMT2A 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.